Which adults (≥18 years) qualify for CAPVAXIVE (PCV21) and what is the recommended pneumococcal vaccination schedule for these patients?

CAPVAXIVE (PCV21) Eligible Populations and Pneumococcal Vaccination Schedule

CAPVAXIVE (PCV21) is recommended as an option for all adults aged ≥50 years who have not received a pneumococcal conjugate vaccine, as well as adults aged 19-49 years with specific risk conditions including immunocompromising conditions, chronic medical conditions, CSF leaks, or cochlear implants. 1

Eligible Adult Populations for CAPVAXIVE

Age-Based Recommendations

• All adults aged ≥50 years who are PCV-naïve (never received PCV13, PCV15, PCV20, or PCV21) 2
• All adults aged ≥65 years regardless of prior vaccination status, with specific timing based on vaccination history 1

Risk-Based Recommendations (Ages 19-64 Years)

Adults with immunocompromising conditions: 1

• Chronic renal failure or nephrotic syndrome
• Immunodeficiency (congenital or acquired)
• Iatrogenic immunosuppression
• Generalized malignancy
• HIV infection
• Hodgkin disease, leukemia, lymphoma, multiple myeloma
• Solid organ transplant recipients
• Congenital or acquired asplenia
• Sickle cell disease or other hemoglobinopathies

Adults with anatomic/functional conditions: 1

• Cerebrospinal fluid (CSF) leak
• Cochlear implant

Adults aged 19-64 years with chronic medical conditions: 1

• Alcoholism
• Chronic heart disease (including congestive heart failure and cardiomyopathies)
• Chronic liver disease
• Chronic lung disease (including COPD, emphysema, and asthma)
• Cigarette smoking
• Diabetes mellitus

Pneumococcal Vaccination Schedule with CAPVAXIVE

For Adults with NO Prior Pneumococcal Vaccination

Adults aged ≥50 years (PCV-naïve): 1

• Single dose of PCV21, PCV20, or PCV15
• If PCV15 is used: Follow with PPSV23 ≥1 year later (≥8 weeks for immunocompromised)
• If PCV21 or PCV20 is used: Series is complete—no additional doses needed

For Adults with Prior PPSV23 Only

All eligible adults: 1

• Single dose of PCV21, PCV20, or PCV15 ≥1 year after the last PPSV23 dose
• If PCV15 is used: Follow with PPSV23 (timing depends on age/risk status)
• If PCV21 or PCV20 is used: Series is complete

For Adults with Prior PCV13 Only

Adults aged ≥65 years: 1

• Single dose of PCV21, PCV20, or PPSV23 ≥1 year after PCV13
• When PPSV23 is used for immunocompromised patients: Give ≥8 weeks after PCV13

Adults aged 19-64 years with immunocompromising conditions: 1

• Single dose of PCV21, PCV20, or PPSV23
• If PCV21 or PCV20: Give ≥1 year after PCV13
• If PPSV23: Give ≥8 weeks after PCV13, then consider PCV21/PCV20 ≥5 years later

Adults aged 19-64 years with chronic medical conditions only: 1

• Single dose of PCV21, PCV20, or PPSV23 ≥1 year after PCV13

For Adults with Prior PCV13 and PPSV23

If PPSV23 was given at age <65 years: 1

• Single dose of PCV21, PCV20, or PPSV23
• If PCV21 or PCV20: Give ≥5 years after the last pneumococcal vaccine dose
• Series is complete after PCV21 or PCV20—no additional doses needed

If PPSV23 was given at age ≥65 years (series already complete): 1

• Shared clinical decision-making regarding PCV21 or PCV20
• If decision is made to vaccinate: Give ≥5 years after the last pneumococcal vaccine dose
• This represents an optional additional dose, not a required vaccination

For immunocompromised adults with PCV13 and 1 dose of PPSV23: 1

• Single dose of PCV21 or PCV20 ≥5 years after the last pneumococcal vaccine dose completes the series
• Alternative: Second PPSV23 dose (≥8 weeks after PCV13 and ≥5 years after first PPSV23)

Critical Timing Intervals

Standard Intervals (Immunocompetent Adults)

• Between PCV and PPSV23: ≥1 year 1, 3
• After prior PPSV23 before giving PCV: ≥1 year 1
• After prior PCV13 before giving PCV21/PCV20: ≥1 year 1
• After completing PCV13 + PPSV23 series before optional PCV21/PCV20: ≥5 years 1

Shortened Intervals (Immunocompromised Adults)

• Between PCV15 and PPSV23: ≥8 weeks 1
• Between PCV13 and PPSV23: ≥8 weeks 1
• After prior PCV13 before giving PCV21/PCV20: ≥1 year (same as immunocompetent) 1

Important Clinical Considerations

When the Series is Complete

Once PCV21 or PCV20 is administered, the pneumococcal vaccination series is complete and no additional pneumococcal vaccines are needed in most scenarios. 1 This simplifies vaccination compared to older PCV13/PPSV23 sequential regimens.

Special Serotype Coverage Consideration

In populations where ≥30% of pneumococcal disease is due to serotype 4, PCV20 alone or PCV15 + PPSV23 may provide broader local serotype coverage than PCV21, as PCV21 does not contain serotype 4. 1

Contraindications

• Severe allergic reaction (anaphylaxis) to any vaccine component 1
• Severe allergic reaction to any diphtheria toxoid-containing vaccine (for PCVs) 1

Coadministration

PCV21 may be administered with other age-appropriate vaccines at the same visit for adults with no specific contraindications. 1 However, pneumococcal vaccines should not be coadministered with each other on the same day. 3, 4

Common Pitfalls to Avoid

• Do not give PCV21/PCV20 too soon: Minimum intervals must be observed for optimal immune response 1
• Do not add PPSV23 after PCV21 or PCV20: Once these higher-valent conjugate vaccines are given, the series is complete 1
• Do not confuse the 5-year interval: This applies only when both PCV13 and PPSV23 were previously given; otherwise use 1-year intervals 1
• Review vaccination status at age 65: For adults vaccinated before age 65, reassess needs when they turn 65 1